MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: Efficacy of early and late treatments

Mayo Clinic Proceedings

Volumn 86, Issue 10, 2011, Pages 948-955

  Tepper, Stewart J ^a   Kori, Shashidhar H ^b   Goadsby, Peter J ^c   Winner, Paul K ^d   Wang, Min H ^b   Silberstein, Stephen D ^e   Cutrer, F Michael ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAP Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Premiere Res Inst P Beach Neurol   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE; MAP 0004; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIA; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 80053473197     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0093     Document Type: Article

References (28)

1. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210. (Pubitemid 46354128)
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(suppl 1):9-160.
3. Valade D. Early treatment of acute migraine: new evidence of benefits. Cephalalgia. 2009;29(suppl 3):15-21.
4. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20(9):1465-1472. (Pubitemid 39361351)
5. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache. 2006;46(6):914-924. (Pubitemid 43794743)
6. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia. 2005;25(9):735-742. (Pubitemid 41208315)
7. Goadsby PJ, Zanchin G, Geraud G, et al. Early versus non-early intervention in acute migraine-'Act when Mild (AwM)': a double-blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28(4):383-391. (Pubitemid 351341454)
8. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55(1):27-36. (Pubitemid 38067358)
9. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55(1):19-26. (Pubitemid 38067357)
10. Burstein R, Levy D, Jakubowski M. Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris). 2005;161(6-7):658-660. (Pubitemid 40933999)
11. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004;101(12):4274-4279. (Pubitemid 38405919)
12. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia. 2007;27(9):1055-1060. (Pubitemid 47296031)
13. Schoenen J, De Klippel N, Giurgea S, et al. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia. 2008;28(10):1095-1105.
14. Martin VT, Penzien DB, Houle TT, Andrew ME, Lofland KR. The predictive value of abbreviated migraine diagnostic criteria. Headache. 2005;45(9):1102-1112. (Pubitemid 350004900)
15. Aurora SK, Kori SH, Barrodale P, McDonald SA, Haseley D. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache. 2006;46(1):57-63.
16. Moore KH, Hussey EK, Shaw S, Fuseau E, Duquesnoy C, Pakes GE. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia. 1997;17(4):541-550. (Pubitemid 27248492)
17. Rapoport AM, Bigal ME, Tepper SJ, Sheftell FD. Zolmitriptan (Zomig). Expert Rev Neurother. 2004;4(1):33-41.
18. Pollock LA. Dihydroergotamine (D.H.E. 45), a new and effective drug in the treatment of migraine. Rocky Mt Med J. 1946;43(11):895-897.
19. Carpi A, Virno M. The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog. Br J Pharmacol Chemother. 1957;12(2):232-239.
20. Goadsby PJ, Gundlach AL. Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol. 1991;29(1):91-94.
21. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiological study. Brain. 1996;119:249-256.
22. Masterson CG, Durham PL. DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons. Headache. 2010;50(9):1424-1439.
23. Pozo-Rosich P, Oshinsky ML. Dihydroergotamine (DHE) blocks the induction of central sensitization in the trigeminal nucleus caudalis [abstract]. Neurology. 2005;64(suppl 1):A151.
24. Silberstein SD, Young WB, Hopkins MM, Gebeline-Myers C, Bradley KC. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache. 2007;47(6):878-885. (Pubitemid 46944351)
25. Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache. 2009;49(10):1423-1434.
26. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009;49(6):826-837.
27. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011;51(4):507-517.
28. Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo) inhaler. Headache. 2008;48(3):355-367. (Pubitemid 351517766)